Cargando…

Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus

INTRODUCTION: Low-dose interleukin-2 (IL-2) regulates the homeostasis of CD4(+) T cells by modulating the proportions of effector and regulatory T cells, thus reducing disease activity in patients with systemic lupus erythematosus (SLE). However, to date, no research has been carried out on the effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Naidi, Jin, Yuebo, Cheng, Gong, Zhang, Kai, Huang, Bo, Li, Yuhui, He, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392266/
https://www.ncbi.nlm.nih.gov/pubmed/37489616
http://dx.doi.org/10.1080/07853890.2023.2238600
_version_ 1785082917199806464
author Wang, Naidi
Jin, Yuebo
Cheng, Gong
Zhang, Kai
Huang, Bo
Li, Yuhui
He, Jing
author_facet Wang, Naidi
Jin, Yuebo
Cheng, Gong
Zhang, Kai
Huang, Bo
Li, Yuhui
He, Jing
author_sort Wang, Naidi
collection PubMed
description INTRODUCTION: Low-dose interleukin-2 (IL-2) regulates the homeostasis of CD4(+) T cells by modulating the proportions of effector and regulatory T cells, thus reducing disease activity in patients with systemic lupus erythematosus (SLE). However, to date, no research has been carried out on the efficacy of low-dose IL-2 for treating autoimmune thyroid disease (AITD). The aim of this study was to observe the effects of IL-2 on AITD patients with concurrent SLE, and explore potential mechanism of action. METHODS: A retrospective analysis was conducted on 29 SLE patients with concurrent AITD. Among them, 11 patients were in IL-2 therapy group and 18 patients without IL-2 treatment were considered as control group. Two groups had similar disease activities and were treated with comparable regular strategy. Free triiodothyronine (FT3), free thyroxine (FT4), thyroxine(T4), triiodothyronine(T3), thyroid stimulating hormone (TSH), thyroglobulin antibody (TG-Ab), thyroid peroxidase antibody (TPO-Ab) levels and immune cell subgroups were measured. RESULTS: After receiving low-dose IL-2 therapy, the TG-Ab and TPO-Ab levels decreased drastically (TG-Ab p = 0.008, TPO-Ab p = 0.007), and the majority of the AITD patients became seronegative, while there was no discernible change in control group. In IL-2 group, percentage of CD4(+) T cells showed a significant increase after treatment (p = 0.029), with an upward trend in the ratio of regulatory T (Treg) cells to follicular helper T (Tfh) cells (Treg/Tfh). The percentage as well as absolute count of B cells demonstrated a decreasing trend. CONCLUSION: Low-dose IL-2 may downregulate the levels of TG-Ab and TPO-Ab by modulating the immune balance of Treg/Tfh and B-cells, providing new avenue for clinical treatment of AITD.
format Online
Article
Text
id pubmed-10392266
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-103922662023-08-02 Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus Wang, Naidi Jin, Yuebo Cheng, Gong Zhang, Kai Huang, Bo Li, Yuhui He, Jing Ann Med Rheumatology INTRODUCTION: Low-dose interleukin-2 (IL-2) regulates the homeostasis of CD4(+) T cells by modulating the proportions of effector and regulatory T cells, thus reducing disease activity in patients with systemic lupus erythematosus (SLE). However, to date, no research has been carried out on the efficacy of low-dose IL-2 for treating autoimmune thyroid disease (AITD). The aim of this study was to observe the effects of IL-2 on AITD patients with concurrent SLE, and explore potential mechanism of action. METHODS: A retrospective analysis was conducted on 29 SLE patients with concurrent AITD. Among them, 11 patients were in IL-2 therapy group and 18 patients without IL-2 treatment were considered as control group. Two groups had similar disease activities and were treated with comparable regular strategy. Free triiodothyronine (FT3), free thyroxine (FT4), thyroxine(T4), triiodothyronine(T3), thyroid stimulating hormone (TSH), thyroglobulin antibody (TG-Ab), thyroid peroxidase antibody (TPO-Ab) levels and immune cell subgroups were measured. RESULTS: After receiving low-dose IL-2 therapy, the TG-Ab and TPO-Ab levels decreased drastically (TG-Ab p = 0.008, TPO-Ab p = 0.007), and the majority of the AITD patients became seronegative, while there was no discernible change in control group. In IL-2 group, percentage of CD4(+) T cells showed a significant increase after treatment (p = 0.029), with an upward trend in the ratio of regulatory T (Treg) cells to follicular helper T (Tfh) cells (Treg/Tfh). The percentage as well as absolute count of B cells demonstrated a decreasing trend. CONCLUSION: Low-dose IL-2 may downregulate the levels of TG-Ab and TPO-Ab by modulating the immune balance of Treg/Tfh and B-cells, providing new avenue for clinical treatment of AITD. Taylor & Francis 2023-07-25 /pmc/articles/PMC10392266/ /pubmed/37489616 http://dx.doi.org/10.1080/07853890.2023.2238600 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Rheumatology
Wang, Naidi
Jin, Yuebo
Cheng, Gong
Zhang, Kai
Huang, Bo
Li, Yuhui
He, Jing
Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus
title Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus
title_full Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus
title_fullStr Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus
title_full_unstemmed Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus
title_short Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus
title_sort retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus
topic Rheumatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392266/
https://www.ncbi.nlm.nih.gov/pubmed/37489616
http://dx.doi.org/10.1080/07853890.2023.2238600
work_keys_str_mv AT wangnaidi retrospectiveanalysisoflowdoseinterleukin2therapyonchronicautoimmunethyroiddiseasewithconcurrentsystemiclupuserythematosus
AT jinyuebo retrospectiveanalysisoflowdoseinterleukin2therapyonchronicautoimmunethyroiddiseasewithconcurrentsystemiclupuserythematosus
AT chenggong retrospectiveanalysisoflowdoseinterleukin2therapyonchronicautoimmunethyroiddiseasewithconcurrentsystemiclupuserythematosus
AT zhangkai retrospectiveanalysisoflowdoseinterleukin2therapyonchronicautoimmunethyroiddiseasewithconcurrentsystemiclupuserythematosus
AT huangbo retrospectiveanalysisoflowdoseinterleukin2therapyonchronicautoimmunethyroiddiseasewithconcurrentsystemiclupuserythematosus
AT liyuhui retrospectiveanalysisoflowdoseinterleukin2therapyonchronicautoimmunethyroiddiseasewithconcurrentsystemiclupuserythematosus
AT hejing retrospectiveanalysisoflowdoseinterleukin2therapyonchronicautoimmunethyroiddiseasewithconcurrentsystemiclupuserythematosus